Tolerogenic Dendritic Cells in Clinical Practice
The Open Arthritis Journal · 2010
DOI: 10.2174/1876539401003010008 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Open Arthritis Journal, 2010. Verfasst von Catharien M.U. Hilkens und 1 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Dendritic cells (DC) play a critical role in maintaining immune tolerance to self-antigens and have become a promising immunotherapeutic tool for treating autoimmune diseases such as rheumatoid arthritis (RA).Tolerogenic DC (tolDC) with stable immunosuppressive function can be generated in the laboratory.These modified tolDC induce antigen-specific T cell tolerance in vitro and in vivo, and can prevent or reduce pathogenic autoimmune responses in experimental animal models of RA.The current challenge is to translate these findings and to develop tolDC for clinical application.In this review we discuss various key considerations for designing tolDC therapy for RA.
Zitieren
APA
Hilkens, C. M., & Isaacs, J. D. (2010). Tolerogenic Dendritic Cells in Clinical Practice. The Open Arthritis Journal. https://doi.org/10.2174/1876539401003010008
Vancouver
Hilkens CM, Isaacs JD. Tolerogenic Dendritic Cells in Clinical Practice. The Open Arthritis Journal. 2010. doi:10.2174/1876539401003010008
BibTeX
@article{Hilkens2010,
author = {Hilkens, Catharien M.U. and Isaacs, John D.},
title = {Tolerogenic Dendritic Cells in Clinical Practice},
journal = {The Open Arthritis Journal},
year = {2010},
doi = {10.2174/1876539401003010008}
}
EUVIMED